No­var­tis re­port­ed­ly backs off ac­qui­si­tion of Cy­to­ki­net­ics – WSJ

Af­ter No­var­tis CEO Vas Narasimhan down­played ru­mors that his com­pa­ny want­ed to ac­quire the biotech Cy­to­ki­net­ics, the Wall Street Jour­nal re­port­ed Thurs­day that the Big Phar­ma has backed away from the deal in the last sev­er­al days.

A rep­re­sen­ta­tive for No­var­tis told End­points News that the com­pa­ny “doesn’t com­ment on mar­ket ru­mor or spec­u­la­tion,” and Cy­to­ki­net­ics sim­i­lar­ly said it doesn’t com­ment on spec­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER